Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection

[1]  R. Baric,et al.  Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms , 2022, Science Translational Medicine.

[2]  A. Iwasaki,et al.  De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2022, Nature Communications.

[3]  C. del Rio,et al.  COVID-19 Therapeutics for Nonhospitalized Patients. , 2022, JAMA.

[4]  Graham W. Taylor,et al.  SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.

[5]  E. Ghedin,et al.  Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion , 2021, The Journal of infectious diseases.

[6]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[7]  P. Minoprio,et al.  Atypical Prolonged Viral Shedding With Intra-Host SARS-CoV-2 Evolution in a Mildly Affected Symptomatic Patient , 2021, Frontiers in Medicine.

[8]  M. C. Muenker,et al.  De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2021, Nature Communications.

[9]  Malina A. Bakowski,et al.  Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 , 2021, Nature Communications.

[10]  E. Ghedin,et al.  Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion , 2021, medRxiv.

[11]  A. Tanuri,et al.  Intra-host evolution during SARS-CoV-2 prolonged infection , 2021, Virus evolution.

[12]  N. Suárez,et al.  In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2 , 2021, PLoS pathogens.

[13]  K. Rabe,et al.  Key summary of German national treatment guidance for hospitalized COVID-19 patients , 2021, Infection.

[14]  O. Pybus,et al.  Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool , 2021, Virus evolution.

[15]  William T. Harvey,et al.  SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.

[16]  C. Dienemann,et al.  Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis , 2021, Nature Structural & Molecular Biology.

[17]  J. Todd,et al.  SARS-CoV-2 within-host diversity and transmission , 2021, Science.

[18]  W. P. Duprex,et al.  Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape , 2021, Science.

[19]  Janet S. Lee,et al.  Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[20]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[21]  K. Rosenberg.  Remdesivir in The Treatment of COVID-19. , 2021, The American journal of nursing.

[22]  Kezhen Li,et al.  Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection , 2020, Nature Communications.

[23]  David W. Taylor,et al.  Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication , 2020, bioRxiv.

[24]  Gaurav D. Gaiha,et al.  Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.

[25]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[26]  M. Addo,et al.  Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[28]  M. Exner,et al.  SARS‐CoV‐2 outbreak investigation in a German meat processing plant , 2020, EMBO molecular medicine.

[29]  M. Aepfelbacher,et al.  SARS Coronavirus-2 variant tracing within the first Coronavirus Disease 19 clusters in northern Germany , 2020, Clinical Microbiology and Infection.

[30]  V. Calvez,et al.  Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019 , 2020, Clinical Infectious Diseases.

[31]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[32]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[33]  Dominik Noerz,et al.  Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting , 2020, Journal of Clinical Virology.

[34]  Susanne Pfefferle,et al.  Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[35]  Karthik Gangavarapu,et al.  An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar , 2018, Genome Biology.

[36]  Ben Nichols,et al.  VSEARCH: a versatile open source tool for metagenomics , 2016, PeerJ.

[37]  Gabor T. Marth,et al.  Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.

[38]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[39]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .